Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2022-08-29 Regulatory Filings
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934" for the month of August 2022. Form 6-K is used by foreign private issuers to report material information to the SEC that they are required to disclose to their home country's stock exchange or make public in their home country. The content is a press release announcing a Notice of Allowance for a Japanese patent. This type of material, non-periodic disclosure filed on Form 6-K is best categorized under the general regulatory filing category, which is RNS (Regulatory Filings), as there is no specific category for Form 6-K itself, and it is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Since it is a formal SEC filing containing material news, RNS is the most appropriate fit among the provided options, although it is a specific SEC form.
2022-08-29 English
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
Report Publication Announcement Classification · 1% confidence The document explicitly states it is an "Immediate Report" under Israeli regulations (Regulation 4 of the Securities Regulations) and references a Form 6-K filing, which is typically used by foreign private issuers to report material events to the SEC. Crucially, the text states, "Attached hereto is a report on *6-k* *6k29082022_DC_isa.pdf*". Given the very short document length (1771 chars) and the clear indication that the actual report is attached or referenced rather than being the full content itself, this filing fits the definition of a Report Publication Announcement (RPA). It announces the publication of a specific regulatory filing (6-K).
2022-08-29 English
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing used by Foreign Private Issuers to report material information to the SEC, often mirroring the content of a press release. The content itself is a press release dated August 24, 2022, announcing regulatory clearance for amendments to a Phase II clinical trial protocol for their drug Allocetra™. This type of material, non-periodic disclosure by a foreign private issuer is typically captured under the general 'Regulatory Filings' category (RNS) or sometimes as an Earnings Release (ER) if it contained financial results. Since this is a specific regulatory filing (Form 6-K) containing a press release about clinical trial updates, and there is no specific code for Form 6-K, the most appropriate general category for significant, non-periodic regulatory announcements that aren't earnings or management changes is RNS (Regulatory Filings). It is not an ER because it focuses on clinical trial protocol amendments, not financial performance highlights. It is not an RPA because it is the primary disclosure document (Form 6-K containing the press release), not just an announcement *about* the release.
2022-08-24 English
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
Report Publication Announcement Classification · 1% confidence The document is very short (1771 characters) and explicitly states, "Attached hereto is a report on *6-k* *6k24082022_DC_isa.pdf*". This structure—a brief announcement referencing an attached or linked external report (in this case, a Form 6-K filed with the ISA/TASE)—fits the definition of a Report Publication Announcement (RPA). It is not the full 6-K report itself, but the notice of its publication. The presence of regulatory headers (Israel Securities Authority, Tel Aviv Stock Exchange) and the immediate report format confirm it is a regulatory filing announcement.
2022-08-24 English
Financial and operating results for the three and six month periods ended June 30, 2022
Interim / Quarterly Report Classification · 1% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd. It contains unaudited condensed consolidated financial statements for the three and six-month periods ended June 30, 2022. Since it provides comprehensive financial data for an interim period (quarterly/half-year) rather than just an announcement or a full annual report, it is classified as an Interim/Quarterly Report. H1 2022
2022-08-22 English
Financial and operating results for the three and six month periods ended June 30, 2022
Report Publication Announcement Classification · 1% confidence The document is a filing cover page submitted to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states: "Report of Periodic or Interim Report" and mentions that an attachment, specifically a "*6k*" report (referencing an SEC Form 6-K, which is used by foreign private issuers for material current reports), is included. The document itself is very short (1884 characters) and serves primarily to announce the availability of the actual report ('Attached hereto is a report on *6k*'). According to Rule 2, when a document is short and announces the publication of another report, it should be classified as a Report Publication Announcement (RPA).
2022-08-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.